Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the Final Primary Endpoint Report on Objective Response Rate data from a University of Pittsburgh Medical Center ...

Many serious conditions can present with vague or atypical symptoms, making early diagnosis challenging and highlighting the ...

Explore the Neurorecovery Horizon and the R. E. S. E. T. framework, a revolutionary approach to understanding and healing ...

First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. Read ...

(“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of ...

It is tempting to understand muscle's role in the body as a simple mechanical motor. But the truth is much more complex: our ...

Oral tolerance is an immunological phenomenon that results from protein intake and that has systemic effects on inflammation. Previous research has shown that parenteral injection of tolerated ...

The European Union has adopted its target for cutting climate pollution by 2040 and is now working on the policies needed to ...

David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck KGaA, Darmstadt, Germany ...

CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...